NCT05613855

Brief Summary

  1. 1.Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients.
  2. 2.Compare PERFORM score with the currently validated PESI in risk stratification of patients

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2022

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

November 7, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 14, 2022

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

November 14, 2022

Status Verified

November 1, 2022

Enrollment Period

1.4 years

First QC Date

November 7, 2022

Last Update Submit

November 7, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients.

    from 11/2022 to 4/2024

Secondary Outcomes (1)

  • Compare PERFORM score with the currently validated PESI in risk stratification of patients.

    from 11/2022 to 4/2024

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will be on patients wh are above 18 years okd who are daignosed to have pulmonary embolism with CTPA

You may not qualify if:

  • Patients who have contraindications for CTPA eg. Renal impairment
  • Patients diagnosed and treated as PE without doing CTPA.
  • Patients who refuse to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991 May;151(5):933-8.

  • Kurkciyan I, Meron G, Sterz F, Janata K, Domanovits H, Holzer M, Berzlanovich A, Bankl HC, Laggner AN. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med. 2000 May 22;160(10):1529-35. doi: 10.1001/archinte.160.10.1529.

  • Jimenez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010 Aug 9;170(15):1383-9. doi: 10.1001/archinternmed.2010.199.

  • Elias A, Mallett S, Daoud-Elias M, Poggi JN, Clarke M. Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis. BMJ Open. 2016 Apr 29;6(4):e010324. doi: 10.1136/bmjopen-2015-010324.

  • Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010 Jul 15;363(3):266-74. doi: 10.1056/NEJMra0907731. Epub 2010 Jun 30. No abstract available.

  • Yu S, Zhou H, Li Y, Song J, Shao J, Wang X, Xie Z, Qiu C, Sun K. PERFORM: Pulmonary embolism risk score for mortality in computed tomographic pulmonary angiography-confirmed patients. EClinicalMedicine. 2021 May 31;36:100897. doi: 10.1016/j.eclinm.2021.100897. eCollection 2021 Jun.

MeSH Terms

Conditions

Pulmonary Embolism

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Central Study Contacts

Nourhan Safwat Abdelraheem, resiedent doctor

CONTACT

Suzan Salama Sayed, professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

November 7, 2022

First Posted

November 14, 2022

Study Start

November 1, 2022

Primary Completion

April 1, 2024

Study Completion

April 1, 2024

Last Updated

November 14, 2022

Record last verified: 2022-11